In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
As of close of business last night, Integra Lifesciences Holdings Corp’s stock clocked out at $16.44, up 0.31% from its previous closing price of $16.39. In other words, the price has increased by $0.31 from its previous closing price. On the day, 1.05 million shares were traded. IART stock price reached its highest trading level at $16.745 during the session, while it also had its lowest trading level at $15.84.
Ratios:
To gain a deeper understanding of IART’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.64 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 50.85. For the most recent quarter (mrq), Quick Ratio is recorded 0.71 and its Current Ratio is at 1.17. In the meantime, Its Debt-to-Equity ratio is 1.28 whereas as Long-Term Debt/Eq ratio is at 0.88.
On December 02, 2024, Morgan Stanley started tracking the stock assigning a Underweight rating and target price of $20.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 03 ’24 when Schwartz Eric sold 4,070 shares for $24.59 per share. The transaction valued at 100,102 led to the insider holds 59,511 shares of the business.
Schwartz Eric bought 4,070 shares of IART for $100,102 on Dec 03 ’24. On Dec 02 ’24, another insider, McBreen Michael J., who serves as the EVP & President, CSS of the company, sold 1,700 shares for $24.16 each. As a result, the insider received 41,064 and left with 56,182 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IART now has a Market Capitalization of 1269988480 and an Enterprise Value of 2978443008. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.79 while its Price-to-Book (P/B) ratio in mrq is 0.82. Its current Enterprise Value per Revenue stands at 1.849 whereas that against EBITDA is 9.225.
Stock Price History:
The Beta on a monthly basis for IART is 1.27, which has changed by -0.43094498 over the last 52 weeks, in comparison to a change of 0.092895746 over the same period for the S&P500. Over the past 52 weeks, IART has reached a high of $32.66, while it has fallen to a 52-week low of $14.45. The 50-Day Moving Average of the stock is -19.15%, while the 200-Day Moving Average is calculated to be -25.00%.
Shares Statistics:
It appears that IART traded 723.62K shares on average per day over the past three months and 814510 shares per day over the past ten days. A total of 77.17M shares are outstanding, with a floating share count of 66.10M. Insiders hold about 14.38% of the company’s shares, while institutions hold 92.57% stake in the company. Shares short for IART as of 1744675200 were 3459017 with a Short Ratio of 4.78, compared to 1741910400 on 3978327. Therefore, it implies a Short% of Shares Outstanding of 3459017 and a Short% of Float of 7.32.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
A detailed examination of Integra Lifesciences Holdings Corp (IART) is currently in progress, with 10.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is $0.57, with high estimates of $0.64 and low estimates of $0.51.
Analysts are recommending an EPS of between $2.48 and $2.44 for the fiscal current year, implying an average EPS of $2.46. EPS for the following year is $2.72, with 12.0 analysts recommending between $2.85 and $2.67.
Revenue Estimates
In the current quarter, 10 analysts expect revenue to total $381.17M. It ranges from a high estimate of $385M to a low estimate of $379.29M. As of the current estimate, Integra Lifesciences Holdings Corp’s year-ago sales were $368.87MFor the next quarter, 10 analysts are estimating revenue of $417.04M. There is a high estimate of $425.89M for the next quarter, whereas the lowest estimate is $409.2M.
A total of 11 analysts have provided revenue estimates for IART’s current fiscal year. The highest revenue estimate was $1.69B, while the lowest revenue estimate was $1.67B, resulting in an average revenue estimate of $1.68B. In the same quarter a year ago, actual revenue was $1.61BBased on 11 analysts’ estimates, the company’s revenue will be $1.75B in the next fiscal year. The high estimate is $1.77B and the low estimate is $1.72B.
